Drug Trial Radar · NCT00447915
Phase II/III Clinical Study of R484iv (Ibandronic Acid) for Primary Osteoporosis
Last checked: Nov 20, 2026Latest source record: Aug 2, 2012 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,265
Actual
Start
Mar 2007
Primary completion
Aug 2011
Study completion Dec 2011
Sponsor
- Lead sponsor
- Chugai PharmaceuticalIndustry
- Sponsor type
- Industry
- First posted
- Mar 15, 2007
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 60 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To evaluate the efficacy and safety of R484iv by intravenous intermittent administration to patients with primary osteoporosis in comparison with sodium risedronate hydrate (RIS) by oral administration every day. To evaluate also the dose response of R484iv.
Conditions
- Primary Osteoporosis
Interventions
ibandronic acid 0.5mgDrug
0.5mg(i.v.)/month for 35 months
RIS placeboDrug
0 mg(p.o.)/day for 36 months
1.0mg ibandronic acidDrug
1.0mg(i.v.)/month for 35 months
ibandronic acid placeboDrug
0mg(i.v.)/month for 35 months
2.5mg RISDrug
2.5 mg(p.o.)/day for 36 months
Calcium and Vitamine D3Dietary supplement
Calcium 305 mg and Vitamine D3 200IU(p.o.)/day for 36 months
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of vertebral fractureTime frame: 36 months
Locations
4 sites in 1 country. Site status is shown where the registry gives one.
Chubu/Kansai region
Chubu/Kansai, Japan
Chugoku/Kyusyu region
Chugoku/Kyusyu, Japan
Hokkaido/Tohoku region
Hokkaido/Tohoku, Japan
Kanto/Koshinetsu region
Kanto/Koshinetsu, Japan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.